Australia's most trusted source of pharma news
Monday, 11 December 2017
Lost Your Access?
CSL inks $3.35bn blood deal
: CSL has signed a new deal with the National Blood Authority to manufacture and supply blood products, with the government boasting it will deliver $200 million in savings.
Pharmacists unprepared for biosims
: Confidence in pharmacy rose to an all-time high in 2017, a national audit has found, although pharmacists are said to be unprepared for biosimilars.
No-tax pharmas outed by ATO
: A tax office report on the country's largest companies shows some major pharmas had no tax to pay in 2015/16.
Consumers highlight access problems
: Consumers and other stakeholders have told the PBAC they face problems with access to medicines currently listed on the PBS.
Fears of immonutherapy bubble
: With more than 2000 potential immunotherapy treatments in development, there's a scramble for trial patients and growing fears of duplication and failure in research.
Jobs go in Sandoz restructure
: The company has confirmed a number of job losses will result from a restructure revealed late Friday, as the 'operating environment continues to get tougher'.
Hurricane to blame for Aussie drug shorts
: Major storm damage to a key overseas drug-making hub is behind a shortage of key drugs in Australia.
Hot jobs of 2018 and bulletproofing your career
: Which jobs are in demand for 2018 and how do you protect your pharma career -
Pharma in Focus
reveals all in the third part of our 2018 Predictions series.
Pfizer inks CBD deal for Dec 2018 move
: Pfizer has inked a deal to lease the top four floors of a new office building under construction in Clarence Street, Sydney, with a move scheduled for December 2018.
Pfizer looking at Sydney CBD move
: Pfizer has whittled down its list of potential sites for its Australian headquarters with a move to the CBD likely, a property expert says.
$600m in biologicals threatened for 2018
: The addition of new biosimilars to the ARTG means that close to $600 million in annual PBS income is under threat.
Three sponsors led 2017 listings
: With just 23 new drugs PBS listed in 2017, three companies emerged as the most successful in getting their new products reimbursed.
Pharma bosses rank among the best
: Three pharmacos place high in the rankings of the
Wall Street Journal's
250 most effectively managed companies.
HCPs want more drug data
: New US research shows HCPs have a thirst for early information on pipeline drugs ahead of regulatory approvals, while in Australia, the MA code is being blamed for blocking info about early access.
J&J, Sanofi top 'Good Pharma' list
: As Santa finalises his naughty and nice list, two pharmacos are sure to be on a winner, topping a 'good pharma' list for clinical trial transparency.
Novo 'keen' to bring weekly diabetes shot
: Novo Nordisk has a 'keen interest' in bringing recently FDA- approved weekly diabetes treatment
to Australia, although it is keeping quiet on timing.
Pfizer antibiotic sees first generic
Southern Cross has added the first copy of a Pfizer antibiotic to the ARTG in a week which saw a flurry of generic activity.
Lilly, Amgen rev up major drugs
Lilly's Taltz and Amgen's Repatha both won significant extensions from the FDA this week as the companies attempt to build blockbuster futures out of their pipelines.
Big city moves not just about the view
Moves by pharma companies to leave suburban sites for slick new city offices is as much about how they want to be seen as it is about the scenery.
Events & Conferences
© 2003 - 2017 Lush Media
Pharma in Focus
Jolly Good Design